Sarepta Therapeutics, Inc. (LON:0L35)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 1.82B |
| Revenue (ttm) | 1.81B |
| Net Income (ttm) | -42.30M |
| Shares Out | n/a |
| EPS (ttm) | -0.44 |
| PE Ratio | n/a |
| Forward PE | 18.38 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 23,397 |
| Average Volume | 29,786 |
| Open | 24.15 |
| Previous Close | 24.32 |
| Day's Range | 22.74 - 24.75 |
| 52-Week Range | 10.49 - 138.41 |
| Beta | 0.50 |
| RSI | 57.47 |
| Earnings Date | Nov 3, 2025 |
About Sarepta Therapeutics
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat Duchenne muscular dystrophy (Duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping... [Read more]
News
A Peek at Sarepta Therapeutics's Future Earnings
Sarepta Therapeutics (NASDAQ: SRPT) will release its quarterly earnings report on Monday, 2025-11-03. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Sarepta Ther...
Piper Sandler Maintains Neutral Rating on SRPT, Raises Price Target to $16 | SRPT Stock News
Piper Sandler Maintains Neutral Rating on SRPT, Raises Price Target to $16 | SRPT Stock News
Interesting SRPT Put And Call Options For December 19th
Investors in Sarepta Therapeutics Inc (Symbol: SRPT) saw new options begin trading this week, for the December 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down ...
Sarepta Therapeutics to Announce Third Quarter 2025 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report third quarter 2025 financial results after the Nasd...
Tradr Launches 9 Single-Stock 2X ETFs With First-Of-Its-Kind OpenDoor, Gold And AI Exposure
Tradr ETFs has introduced nine new single-stock leveraged ETFs designed to provide twice the daily performance of their underlying stocks. Seven of these ETFs are first-to-market strategies. The first...
Tradr Debuts Leveraged ETFs on BLSH, DASH, FLY, IREN, NEM, OPEN, QS, SRPT & WULF
Funds seek to provide 200% long exposure on a variety of industry leaders NEW YORK , Oct. 23, 2025 /PRNewswire/ -- Tradr ETFs, a provider of ETFs designed for sophisticated investors and professional ...
Sarepta Therapeutics: A Discounted Valuation Meets Breakthrough Pipeline
Sarepta Therapeutics is showing signs of recovery, driven by its robust pipeline and recent revenue growth, despite past clinical setbacks. Learn more about SRPT stock here.
What's Going On Sarepta Stock On Wednesday?
Sarepta Therapeutics Inc. (NASDAQ:SRPT) stock is trading higher on Wednesday, with apparently no news to justify the movement.
Sarepta (SRPT) Faces Medicaid Coverage Pause for Duchenne Treatment
Sarepta (SRPT) Faces Medicaid Coverage Pause for Duchenne Treatment
Sarepta: Q3 Earnings An Upcoming Catalyst, But Risks Undermine Any Contrarian Play
Sarepta Therapeutics faces major risks in 2025 with stock collapse, halted therapies, and financial woes. Click here to read why SRPT is a Hold.
Sarepta Therapeutics (SRPT) Receives Sell Rating Amid Declining Growth
Sarepta Therapeutics (SRPT) Receives Sell Rating Amid Declining Growth
Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2025 World Muscle Society Congress
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present at the 30th Annual Congress of the World Muscle So...
Notable Thursday Option Activity: SRPT, PLAB, SEI
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Sarepta Therapeutics Inc (Symbol: SRPT), where a total volume of 38,397 contracts ...
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on September 30, 2025 (the “Grant Date”) ...
Kuehn Law Encourages Investors of Sarepta Therapeutics, Inc. to Contact Law Firm
NEW YORK , Sept. 24, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) brea...
Sarepta Therapeutics (SRPT) Upgraded to 'Outperform' by BMO Capital | SRPT Stock News
Sarepta Therapeutics (SRPT) Upgraded to 'Outperform' by BMO Capital | SRPT Stock News
This Sarepta Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings pag...
Vanguard Group Inc's Strategic Acquisition of Sarepta Therapeutics Shares
Vanguard Group Inc's Strategic Acquisition of Sarepta Therapeutics Shares
SRPT: Leerink Partners Raises Price Target While Maintaining Rating | SRPT Stock News
SRPT: Leerink Partners Raises Price Target While Maintaining Rating | SRPT Stock News
Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2025-2026 Academic Year
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced 25 recipients of Route 79, The Duchenne Scholar...
SRPT Stock Alert: Investors with Large Losses Should Contact Robbins LLP for Information About the Pending Lead Plaintiff Deadline in the Sarepta Therapeutics, Inc. Class Action
SAN DIEGO, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Sarepta Therapeutics, Inc. (NASDA...
mRNA Biotechs - Long-Term Value Risks Abound
mRNA vaccine companies are overhyped post-pandemic, facing scientific, operational, and regulatory headwinds that limit long-term investment appeal. Scientific and business risks, including delivery c...
Investors in Sarepta Therapeutics, Inc. Should Contact Levi & Korsinsky Before August 25, 2025 to Discuss Your Rights – SRPT
NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT) of a class action securities lawsuit.
SAREPTA FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Sarepta Therapeutics, Inc. and Encourages Investors to Contact the Firm Before the August 25th Deadline
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Sarepta (SRPT) To Contact Him Directly To Discuss Their Options
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics
NEW YORK--(BUSINESS WIRE)---- $SRPT #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Sarepta Therapeutics, Inc. (“Sarepta” or the “...